These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24405885)

  • 1. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
    Nakamura Y; Tsuji M; Hasegawa H; Kimura K; Fujita K; Inoue M; Shimizu T; Gotoh H; Goto Y; Inagaki M; Oguchi K
    Hemodial Int; 2014 Apr; 18(2):433-42. PubMed ID: 24405885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
    Nakamura Y; Inagaki M; Shimizu T; Fujita K; Inoue M; Gotoh H; Oguchi K; Goto Y
    Nephron Clin Pract; 2013; 123(1-2):46-51. PubMed ID: 23774306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
    Grunberger G
    Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
    Lajara R
    Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
    von Websky K; Reichetzeder C; Hocher B
    Vasc Health Risk Manag; 2013; 9():681-94. PubMed ID: 24204157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin as add-on therapy for type 2 diabetes - an overview.
    Brown DX; Choudhury M; Evans M
    Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
    Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
    Koliaki C; Doupis J
    Adv Ther; 2012 Dec; 29(12):993-1004. PubMed ID: 23184570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
    Yamagishi S; Ishibashi Y; Ojima A; Sugiura T; Matsui T
    Int J Cardiol; 2014 Sep; 176(2):550-2. PubMed ID: 25065332
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Clin Ther; 2012 May; 34(5):993-1005. PubMed ID: 22440191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.